検索
Black Diamond Therapeutics Inc
BDTXウォッチリストに追加
2.010USD
+0.170+9.24%
終値 07/02, 13:00（ET）15分遅れの株価
114.46M時価総額
損失額直近12ヶ月PER
詳細情報 Black Diamond Therapeutics Inc 企業名
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Incの企業情報
企業コードBDTX
会社名Black Diamond Therapeutics Inc
上場日Jan 30, 2020
最高経営責任者「CEO」Velleca (Mark A)
従業員数24
証券種類Ordinary Share
決算期末Jan 30
本社所在地245 First Street, 18Th Floor
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02142
電話番号16174175868
ウェブサイトhttps://www.blackdiamondtherapeutics.com/
企業コードBDTX
上場日Jan 30, 2020
最高経営責任者「CEO」Velleca (Mark A)
Black Diamond Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
よくある質問
Black Diamond Therapeutics Incの上位5名の株主は誰ですか？
Black Diamond Therapeutics Incの上位5名の株主は以下のとおりです。Dr. Ali Behbahani, M.D.
Black Diamond Therapeutics Inc（BDTX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Black Diamond Therapeutics Incの株式を保有している機関は265社あり、保有株式の総市場価値は約45.02Mで、全体の78.72%を占めています。2025Q4と比較して、機関の持ち株は-14972289.00増加しています。